Lobe Sciences Ltd.
CNQ: LOBE.CN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Canadian Securities Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Frederick Dominick Sancilio
- Headquarters
- Vancouver, Canada
- IPO year
- 2012
- Market cap
- CA$25.1M
- Website
- https://www.lobesciences.com
Loading LOBE…
Loading profile data…Frequently asked questions about LOBE
What does Lobe Sciences Ltd. (LOBE.CN) do?
Lobe Sciences Ltd., a life sciences company, focuses on the research and development of psychedelic medicines. It develops psilocybin-based therapeutics in combination with N-acetylcysteine for the treatment of mild traumatic brain injuries and post-traumatic stress disorder, as well as devices for the efficient application of medications. The c...
Where does LOBE.CN trade?
Lobe Sciences Ltd. (LOBE.CN) trades on the Canadian Securities Exchange.
What sector is LOBE.CN in?
Lobe Sciences Ltd. (LOBE.CN) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Lobe Sciences Ltd.?
Frederick Dominick Sancilio is the chief executive officer of Lobe Sciences Ltd. (LOBE.CN).
Where is Lobe Sciences Ltd. headquartered?
Lobe Sciences Ltd. is headquartered in Canada.
Does LOBE.CN pay a dividend?
Lobe Sciences Ltd. (LOBE.CN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did LOBE.CN go public?
Lobe Sciences Ltd. (LOBE.CN) completed its initial public offering in 2012.